Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 23157612)

1.

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.

Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B.

J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1252-61. doi: 10.1111/j.1468-3083.2012.04705.x. Epub 2012 Nov 16.

PMID:
23157612
2.

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.

Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM.

J Invest Dermatol. 2012 Feb;132(2):304-14. doi: 10.1038/jid.2011.304. Epub 2011 Oct 20.

3.

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.

Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M.

J Am Acad Dermatol. 2014 Dec;71(6):1176-82. doi: 10.1016/j.jaad.2014.07.048. Epub 2014 Sep 19.

PMID:
25242558
4.

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A.

JAMA. 2011 Aug 24;306(8):864-71. doi: 10.1001/jama.2011.1211.

PMID:
21862748
5.

Briakinumab for the treatment of plaque psoriasis.

Traczewski P, Rudnicka L.

BioDrugs. 2012 Feb 1;26(1):9-20. doi: 10.2165/11595940-000000000-00000. Review.

PMID:
22077474
6.

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.

Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA.

Br J Dermatol. 2011 Sep;165(3):661-8. doi: 10.1111/j.1365-2133.2011.10419.x. Epub 2011 Jul 28.

PMID:
21574984
7.

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, Valdes JM.

N Engl J Med. 2011 Oct 27;365(17):1586-96. doi: 10.1056/NEJMoa1010858.

8.

Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

Hamilton T, Menter A, Caro I, Compton P, Sobell J, Papp KA.

Drug Saf. 2008;31(8):715-26.

PMID:
18636790
9.

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.

Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J; ABT-874 Psoriasis Study Investigators.

Arch Dermatol. 2008 Feb;144(2):200-7. doi: 10.1001/archdermatol.2007.63.

PMID:
18283176
10.

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. Review.

11.

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB; PHOENIX 1, PHOENIX 2, and ACCEPT investigators.

J Drugs Dermatol. 2012 Mar;11(3):300-12.

PMID:
22395580
12.

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators.

Br J Dermatol. 2013 Apr;168(4):844-54. doi: 10.1111/bjd.12214.

PMID:
23301632
13.

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, Li S, Hsu MC, Strober B.

J Am Acad Dermatol. 2012 May;66(5):731-41. doi: 10.1016/j.jaad.2011.06.011. Epub 2011 Sep 17.

PMID:
21930328
14.

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.

Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA.

Br J Dermatol. 2011 Sep;165(3):652-60. doi: 10.1111/j.1365-2133.2011.10418.x. Epub 2011 Aug 4.

PMID:
21574983
15.

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.

Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K.

J Am Acad Dermatol. 2012 May;66(5):742-51. doi: 10.1016/j.jaad.2011.06.041. Epub 2011 Oct 5.

PMID:
21978572
16.

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.

Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen YK, Leonardi C; PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups.

Br J Dermatol. 2012 Nov;167(5):1145-52. doi: 10.1111/j.1365-2133.2012.11142.x.

PMID:
22803615
17.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators.

Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6.

PMID:
18486740
18.

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group.

N Engl J Med. 2007 Feb 8;356(6):580-92.

19.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000.

PMID:
21110526
20.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators.

Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4. Erratum in: Lancet. 2008 May 31;371(9627):1838.

PMID:
18486739
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk